A citation-based method for searching scientific literature

Filip Janku, Timothy A Yap, Funda Meric-Bernstam. Nat Rev Clin Oncol 2018
Times Cited: 394







List of co-cited articles
591 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


The PI3K Pathway in Human Disease.
David A Fruman, Honyin Chiu, Benjamin D Hopkins, Shubha Bagrodia, Lewis C Cantley, Robert T Abraham. Cell 2017
767
16


Targeting PI3K in cancer: mechanisms and advances in clinical trials.
Jing Yang, Ji Nie, Xuelei Ma, Yuquan Wei, Yong Peng, Xiawei Wei. Mol Cancer 2019
326
12

Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.
Fabrice André, Eva Ciruelos, Gabor Rubovszky, Mario Campone, Sibylle Loibl, Hope S Rugo, Hiroji Iwata, Pierfranco Conte, Ingrid A Mayer, Bella Kaufman,[...]. N Engl J Med 2019
616
12

AKT/PKB Signaling: Navigating the Network.
Brendan D Manning, Alex Toker. Cell 2017
10

PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting.
Lauren M Thorpe, Haluk Yuzugullu, Jean J Zhao. Nat Rev Cancer 2015
695
10

PI3K and cancer: lessons, challenges and opportunities.
David A Fruman, Christian Rommel. Nat Rev Drug Discov 2014
8

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L Siegel, Lindsey A Torre, Ahmedin Jemal. CA Cancer J Clin 2018
8

Targeting the phosphoinositide 3-kinase pathway in cancer.
Pixu Liu, Hailing Cheng, Thomas M Roberts, Jean J Zhao. Nat Rev Drug Discov 2009
8

mTOR Signaling in Growth, Metabolism, and Disease.
Robert A Saxton, David M Sabatini. Cell 2017
8


The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism.
Jeffrey A Engelman, Ji Luo, Lewis C Cantley. Nat Rev Genet 2006
7

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex.
D D Sarbassov, David A Guertin, Siraj M Ali, David M Sabatini. Science 2005
6

Challenges for the Clinical Development of PI3K Inhibitors: Strategies to Improve Their Impact in Solid Tumors.
Ariella B Hanker, Virginia Kaklamani, Carlos L Arteaga. Cancer Discov 2019
58
10

High frequency of mutations of the PIK3CA gene in human cancers.
Yardena Samuels, Zhenghe Wang, Alberto Bardelli, Natalie Silliman, Janine Ptak, Steve Szabo, Hai Yan, Adi Gazdar, Steven M Powell, Gregory J Riggins,[...]. Science 2004
6

Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
José Baselga, Seock-Ah Im, Hiroji Iwata, Javier Cortés, Michele De Laurentiis, Zefei Jiang, Carlos L Arteaga, Walter Jonat, Mark Clemons, Yoshinori Ito,[...]. Lancet Oncol 2017
285
6

RAS Proteins and Their Regulators in Human Disease.
Dhirendra K Simanshu, Dwight V Nissley, Frank McCormick. Cell 2017
516
6

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.
Jeffrey A Engelman, Liang Chen, Xiaohong Tan, Katherine Crosby, Alexander R Guimaraes, Rabi Upadhyay, Michel Maira, Kate McNamara, Samanthi A Perera, Youngchul Song,[...]. Nat Med 2008
6

Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer: A Phase 1b Clinical Trial.
Dejan Juric, Filip Janku, Jordi Rodón, Howard A Burris, Ingrid A Mayer, Martin Schuler, Ruth Seggewiss-Bernhardt, Marta Gil-Martin, Mark R Middleton, José Baselga,[...]. JAMA Oncol 2019
89
6

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.
José Baselga, Mario Campone, Martine Piccart, Howard A Burris, Hope S Rugo, Tarek Sahmoud, Shinzaburo Noguchi, Michael Gnant, Kathleen I Pritchard, Fabienne Lebrun,[...]. N Engl J Med 2012
6



PI3K signalling in inflammation.
P T Hawkins, L R Stephens. Biochim Biophys Acta 2015
241
5

PI3K inhibitors: review and new strategies.
Mingzhen Zhang, Hyunbum Jang, Ruth Nussinov. Chem Sci 2020
23
21

Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors.
Neil Vasan, Pedram Razavi, Jared L Johnson, Hong Shao, Hardik Shah, Alesia Antoine, Erik Ladewig, Alexander Gorelick, Ting-Yu Lin, Eneda Toska,[...]. Science 2019
68
7

PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer.
Ana Bosch, Zhiqiang Li, Anna Bergamaschi, Haley Ellis, Eneda Toska, Aleix Prat, Jessica J Tao, Daniel E Spratt, Nerissa T Viola-Villegas, Pau Castel,[...]. Sci Transl Med 2015
181
5

A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2- advanced breast cancer (BELLE-4).
M Martín, A Chan, L Dirix, J O'Shaughnessy, R Hegg, A Manikhas, M Shtivelband, P Krivorotko, N Batista López, M Campone,[...]. Ann Oncol 2017
84
5

Class I phosphatidylinositol 3-kinase inhibitors for cancer therapy.
Wennan Zhao, Yuling Qiu, Dexin Kong. Acta Pharm Sin B 2017
73
6

Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor.
Dejan Juric, Pau Castel, Malachi Griffith, Obi L Griffith, Helen H Won, Haley Ellis, Saya H Ebbesen, Benjamin J Ainscough, Avinash Ramu, Gopa Iyer,[...]. Nature 2015
319
5

mTOR kinase structure, mechanism and regulation.
Haijuan Yang, Derek G Rudge, Joseph D Koos, Bhamini Vaidialingam, Hyo J Yang, Nikola P Pavletich. Nature 2013
521
5

Suppression of insulin feedback enhances the efficacy of PI3K inhibitors.
Benjamin D Hopkins, Chantal Pauli, Xing Du, Diana G Wang, Xiang Li, David Wu, Solomon C Amadiume, Marcus D Goncalves, Cindy Hodakoski, Mark R Lundquist,[...]. Nature 2018
220
5

Phosphatidylinositol 3-Kinase α-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study.
Dejan Juric, Jordi Rodon, Josep Tabernero, Filip Janku, Howard A Burris, Jan H M Schellens, Mark R Middleton, Jordan Berlin, Martin Schuler, Marta Gil-Martin,[...]. J Clin Oncol 2018
154
5

Cancer statistics, 2020.
Rebecca L Siegel, Kimberly D Miller, Ahmedin Jemal. CA Cancer J Clin 2020
5


Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal.
Jianjiong Gao, Bülent Arman Aksoy, Ugur Dogrusoz, Gideon Dresdner, Benjamin Gross, S Onur Sumer, Yichao Sun, Anders Jacobsen, Rileen Sinha, Erik Larsson,[...]. Sci Signal 2013
5

A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2- Metastatic Breast Cancer.
Ingrid A Mayer, Vandana G Abramson, Luigi Formisano, Justin M Balko, Mónica V Estrada, Melinda E Sanders, Dejan Juric, David Solit, Michael F Berger, Helen H Won,[...]. Clin Cancer Res 2017
168
5

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt.
Kathryn E O'Reilly, Fredi Rojo, Qing-Bai She, David Solit, Gordon B Mills, Debra Smith, Heidi Lane, Francesco Hofmann, Daniel J Hicklin, Dale L Ludwig,[...]. Cancer Res 2006
5

CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors.
Sadhna R Vora, Dejan Juric, Nayoon Kim, Mari Mino-Kenudson, Tiffany Huynh, Carlotta Costa, Elizabeth L Lockerman, Sarah F Pollack, Manway Liu, Xiaoyan Li,[...]. Cancer Cell 2014
264
5

CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability.
Brian J Lannutti, Sarah A Meadows, Sarah E M Herman, Adam Kashishian, Bart Steiner, Amy J Johnson, John C Byrd, Jeffrey W Tyner, Marc M Loriaux, Mike Deininger,[...]. Blood 2011
544
5

Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials.
Christine Fritsch, Alan Huang, Christian Chatenay-Rivauday, Christian Schnell, Anupama Reddy, Manway Liu, Audrey Kauffmann, Daniel Guthy, Dirk Erdmann, Alain De Pover,[...]. Mol Cancer Ther 2014
244
5

Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor.
Sauveur-Michel Maira, Sabina Pecchi, Alan Huang, Matthew Burger, Mark Knapp, Dario Sterker, Christian Schnell, Daniel Guthy, Tobi Nagel, Marion Wiesmann,[...]. Mol Cancer Ther 2012
382
5

Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.
Sarah E M Herman, Amber L Gordon, Amy J Wagner, Nyla A Heerema, Weiqiang Zhao, Joseph M Flynn, Jeffrey Jones, Leslie Andritsos, Kamal D Puri, Brian J Lannutti,[...]. Blood 2010
425
5

PI3K/AKT signaling pathway and cancer: an updated review.
Miriam Martini, Maria Chiara De Santis, Laura Braccini, Federico Gulluni, Emilio Hirsch. Ann Med 2014
582
5

PTEN and the PI3-kinase pathway in cancer.
Nader Chalhoub, Suzanne J Baker. Annu Rev Pathol 2009
749
5

Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.
Ahmet Zehir, Ryma Benayed, Ronak H Shah, Aijazuddin Syed, Sumit Middha, Hyunjae R Kim, Preethi Srinivasan, Jianjiong Gao, Debyani Chakravarty, Sean M Devlin,[...]. Nat Med 2017
4

Global cancer statistics, 2012.
Lindsey A Torre, Freddie Bray, Rebecca L Siegel, Jacques Ferlay, Joannie Lortet-Tieulent, Ahmedin Jemal. CA Cancer J Clin 2015
4


Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha.
D R Alessi, S R James, C P Downes, A B Holmes, P R Gaffney, C B Reese, P Cohen. Curr Biol 1997
4

The Emerging Hallmarks of Cancer Metabolism.
Natalya N Pavlova, Craig B Thompson. Cell Metab 2016
4

Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors.
Dejan Juric, Ian Krop, Ramesh K Ramanathan, Timothy R Wilson, Joseph A Ware, Sandra M Sanabria Bohorquez, Heidi M Savage, Deepak Sampath, Laurent Salphati, Ray S Lin,[...]. Cancer Discov 2017
89
4


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.